Safety check of a repurposed drug with Keytruda plus Lenvima
Treatments studied
Part of Cancer clinical trials.
This Phase 2 trial tests whether a repurposed drug can be safely added to Keytruda and Lenvima for women with advanced or recurrent endometrial cancer. It’s meant to help people who can’t have curative surgery or radiation after prior chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman age 18 or older with endometrial (uterine) cancer confirmed by biopsy.
- Your tumor is not MSI-H and not dMMR (mismatch repair is normal or only partially affected).
- Your cancer is advanced (stage III/IV) or has come back, and it has progressed after a platinum chemo drug.
- You either can start, or are already taking, Keytruda plus Lenvima (Lenvima/lenvatinib + Keytruda/pembrolizumab) at the study doses.
- You have measurable or evaluable tumors on scans, and you have at least 12 weeks of expected life.
- Your health tests meet safety limits: good activity level (ECOG 0–1), controlled blood pressure, and acceptable kidney function.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 study tests whether adding a repurposed drug to Keytruda and Lenvima (Len+Pem) helps people with advanced or recurrent endometrial cancer live longer and feel safer. It is designed for tumors that do not have certain immune-system markers (not MSI-H or dMMR).
This Phase 2 trial tests whether envafolimab alone or combined with lenvatinib can slow or shrink advanced endometrial (uterine) cancer. It’s for people whose cancer has grown again or spread and who didn’t do well with standard platinum chemotherapy.
This trial tests a combination of two drugs (pembrolizumab and lenvatinib) for endometrial cancer that has come back after initial treatment with chemotherapy and immunotherapy. The study focuses on a specific type of cancer based on genetic testing and may help patients whose cancer didn't respond to standard first-line treatment.
This study tests a new drug (PF-08634404) combined with chemotherapy for women with advanced or recurrent endometrial cancer that is MMR-proficient. The goal is to see if this combination works better than standard care.
This study tests a combination of two drugs (lenvatinib and pembrolizumab) plus focused radiation to the pelvis for a specific type of endometrial cancer that has returned or cannot be surgically removed. The goal is to see if this treatment is safe and effective for tumors that are pMMR and limited to the pelvic area.
This trial tests a combination of two investigational drugs—anlotinib (a capsule that blocks blood supply to tumors) and TQB2450 (an immunotherapy that helps your immune system attack cancer cells)—for people with recurrent or metastatic endometrial cancer that has not responded to previous platinum-based chemotherapy. The goal is to see if this combo can shrink tumors or slow their growth.
Hear when a new Advanced Endometrial Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.